ERBB2 and breast cancer: During follow‐up of HER2‐negative stage II‐III BC, detection of CTCs (5.1% of patients) between 4.5 and 7.5 years after primary surgical treatment was associated with a 13.1‐fold higher risk of recurrence [29].